Abstract:Background: Early evaluation and treatment of patients with suspected acute coronary syndrome (ACS) poses a huge challenge to the emergency care system worldwide, but little is known about the contemporary prehospital and emergency department management of these patients. We aimed to investigate the early evaluation, treatment, and outcome of suspected ACS in a representative population of China. Methods: We did a prospective registry study involving a network of 23 emergency departments in China. Each participating site consecutively enrolled adult patients presenting with symptoms suggestive of ACS for at least 12 months between August 2015 and September 2017. All findings were weighted by sampling ratio and variation among EDs in enrollment period. Findings: A total of 13 919 patients were screened. Of those included in the analysis, mean age was 63·8±13·6 years, 57·9% were men. After symptom onset, 40·5% of the patients arrived at emergency department within two hours, and 17·9% were transported by ambulance. Upon arrival to the emergency department, 75·6% had their first ECG completed within ten minutes. Among patients without ST-segment elevation, 10·3% had serial ECGs, 56·6% had serum cardiac biomarkers measured, and 6·4% had serial cardiac biomarkers. Stress test and computed tomography angiography were rarely performed for evaluation. Among patients with ST-segment elevation, 57·3% underwent reperfusion therapy, with 51·3% receiving primary percutaneous coronary intervention and 6·3% receiving fibrinolysis. Post-hoc adjudication showed that over 60% of patients could be attributed to ACS, of which 10·2% received antiplatelet therapy prior to presentation, and by the time of emergency department disposition, 51·1% received antiplatelet therapy. Overall, the emergency department mortality rate was 0·5%, and the 30-day mortality and major adverse cardiac event rates were 3·8% and 6·8%, respectively. Interpretation: The pre-hospital and emergency department evaluation of patients with suspected ACS is insufficient in China. For those with ACS, gaps existed in the early medication and reperfusion therapy as per guidelines. These findings suggest opportunities to improve the quality of early management for suspected ACS and further reduce adverse cardiac events in China. Clinical Trial Registration Details: This study was registered at URL: https://www.clinicaltrials.gov (Unique identifier: NCT02536677). Funding Information: This work was supported by National S&T Fundamental Resources Investigation Project [2018FY100600, 2018FY100602], Shandong Provincial Natural Science Foundation [ZR2017PH070], Taishan Pandeng Scholar Program of Shandong Province [tspd20181220], Taishan Young Scholar Program of Shandong Province [tsqn20161065, tsqn201812129], Key R&D Program of Shandong Province [2020SFXGFY03, 2019GSF108073] and Qilu Young Scholar Program. Declaration of Interests: All authors declare no competing interests. Ethics Approval Statement: The study complies with the Declaration of Helsinki and was approved by the ethical committees of all participating sites. Informed consent was required from each patient to participate in the study.

Evaluation of Metoprolol Standard Dosing Pathway in Chinese Patients with Acute Coronary Syndrome: a Prospective Multicenter Single-Arm Interventional Study

Occurrence of composite cardiac endpoints with change in resting heart rate among Chinese patients with coronary artery disease: Chinese cohort from the real-world BISO-CAD study.

Effects of Metoprolol on Periprocedural Myocardial Infarction after Percutaneous Coronary Intervention (type 4a MI): an Inverse Probability of Treatment Weighting Analysis

Heart Rate Control is Associated with Reduced Cardiovascular Events in Asian Patients with Coronary Artery Disease Treated with Bisoprolol (BISO-CAD): Results from a Multi-National, Real-World Experience

Effect of Metoprolol Succinate in Patients with Stable Angina and Elevated Heart Rate Receiving Low-Dose β-Blocker Therapy.

Effect Of Metoprolol Succinate In Patients With Stable Angina And Elevated Heart Rate Receiving Low-Dose Beta-Blocker Therapy

Efficacy and Safety of Serial Atorvastatin Load in Chinese Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the ISCAP (intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) Randomized Controlled Trial

The effectiveness and safety of Chinese Patent Medicines based on syndrome differentiation in patients following percutaneous coronary intervention due to acute coronary syndrome (CPM trial): A nationwide Cohort Study

Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.

E0258 Current Clinical Practice and Guideline Application in Therapies of ST Segment Elevation ACS Inpatient in a Multi-Provincial Study in China: Results of BRIG Project

[Effect of Pathway Training on Rest Heart Rate and the Application of Β-Blocker in Coronary Heart Disease Patients: an Open-Label, Multi-Center, Prospective Study].

A randomized, placebo-controlled, double-blind trial to evaluate efficacy and safety of Shen-Yuan-Dan capsules, a traditional Chinese medicine, for treatment of peri-procedure myocardial injury following percutaneous coronary intervention

Evaluation, Treatment, and Outcomes of Patients with Suspected Acute Coronary Syndrome in the Prehospital and Emergency Department: Findings from a Prospective Multicenter Registry in China

G-002 AMLODIPINE/VALSARTAN 5/160 MG VERSUS VALSARTAN 160 MG IN PREDOMINANTLY CHINESE PATIENTS WITH STAGE 1 OR 2 ESSENTIAL HYPERTENSION NOT ADEQUATELY CONTROLLED ON VALSARTAN 160 MG MONOTHERAPY

Analysis of Efficacy and Safety of the Target Dose of Metoprolol in Treatment of Patinets with Chronic Heart Failure and Diabetes Mellitus

Early β-blocker use and in-hospital outcomes in patients with chronic obstructive pulmonary disease hospitalized with acute coronary syndrome: findings from the CCC-ACS project

China STudy of Valsartan/amlodipine Fixed-Dose Combination-Based Long-Term Blood Pressure Management in HypertenSive Patients: a One-Year Registry (china STATUS III)

Clinical Observation on Full Dosage Metoprolol Administered in the Earlier Stage of Acute Myocardial Infarction

Efficacy of Danlou tablets in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a multicenter prospective cohort study

Efficacy and Safety of Valsartan/Amlodipine Single-Pill Combination in 11,422 Chinese Patients with Hypertension: an Observational Study

Comparison of antiangina therapies in patients with coronary heart disease in China: study protocol for a multicentre, retrospective, hospital system-based study